Renal angiomyolipoma

USG · CT · MRI

First and second year — the floor first, then every step

An echogenic renal lesion raises AML; ultrasound cannot prove fat and cannot distinguish a small echogenic RCC.

Orient first

  • AML is typically a well-defined hyperechoic renal mass. A small RCC can look identical.
  • Acoustic shadowing and a speed-of-sound artefact are suggestions, not proofs. The confirming test is non-contrast CT or MRI.
  • Colour Doppler may show internal vessels; their presence does not make the diagnosis and their absence does not exclude it.

Acquire the study

  • Scan both kidneys with a curvilinear probe; measure the lesion in three planes; apply colour Doppler with settings for slow flow.
  • Do not offer AML as a conclusion — offer it as the reason for non-contrast CT or MRI.

The manoeuvre

  • Confirm the mass arises from renal parenchyma on grey-scale, not from perinephric fat or the adrenal, by showing a claw of cortex around it.
  • Describe echogenicity against cortex at the SAME depth, posterior acoustic features, and internal colour Doppler flow.
  • Name non-contrast CT (or fat-saturated MRI) as the study that can prove macroscopic fat, rather than concluding AML.

What confirms it

  • A renal mass containing macroscopic fat, without calcification, is an angiomyolipoma until a rare fat-containing RCC is specifically suspected (calcification, invasion, lymphadenopathy).

What licenses you to exclude it

  • ⚠️ ABSENCE OF VISIBLE FAT DOES NOT EXCLUDE AML — fat-poor AML is a real entity and needs the same work-up as any other solid renal mass.
  • Ultrasound cannot exclude AML and cannot confirm it. An echogenic renal lesion is an AML only when CT or MRI has shown fat.

The classic misread

  • Calling an echogenic renal lesion an angiomyolipoma on ultrasound alone.

Reference values

Each value carries the caveat that keeps it from being misused. Normal limits and diagnostic criteria are kept apart on purpose: a disease cut-off read as a normal range is the more dangerous mistake.

Diagnostic criteria

  • Renal mass · Size as used in T-staging and active-surveillance discussions

    a named staging input: T1a is 4 cm or less, T1b is over 4 to 7 cm, T2 over 7 cm — TNM edition must be named; surveillance pathways use their own size bands

    Size is one axis of T-stage; perinephric fat, venous and collecting-system invasion are others. Do not quote an edition year from memory — name "current TNM" and verify. Versioned criterion — verify against the current edition before clinical use.

    CT · MRI · USG

  • Fat-containing lesions · Attenuation of macroscopic fatat or below −10 HU

    Macroscopic fat in a renal mass makes angiomyolipoma the leading diagnosis (in the absence of calcification), and supports adrenal myelolipoma or ovarian dermoid in those organs — but fat-poor AML exists, so absence of fat excludes nothing.

    CT

See it on real cases

Direct links to Radiopaedia — the reference article and worked cases with their images. Each opens on Radiopaedia.

Key papers

Reviews and guidelines from RSNA, ESR and related journals. Each opens at its DOI.

  1. Spectrum of Renal Angiomyolipoma with Radiologic-Pathologic Correlation ↗Lubner MG, Marko J, Taffel MT, et al. · RadioGraphics 2025RSNA · PubMed
  2. Renal Angiomyolipoma: Radiologic Classification and Imaging Features According to the Amount of Fat ↗Park BK · AJR 2017ARRS · PubMed
  3. Renal angiomyolipoma without visible fat: Can we make the diagnosis using CT and MRI? ↗Lim RS, Flood TA, McInnes MDF, et al. · European Radiology 2018ESR · PubMed
  4. Chemical shift magnetic resonance imaging for distinguishing minimal-fat renal angiomyolipoma from renal cell carcinoma: a meta-analysis ↗Chen LS, Zhu ZQ, Wang ZT, et al. · European Radiology 2018ESR · PubMed

More searches

More in Abdomen and pelvis